Search clinical trials for: Intravenous Placebo for NTM-001

Total 4728 results

Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
Cerenis Therapeutics, SA
South Australian Health and Medical Research Institute

Completed

CER-001 Atherosclerosis Regression ACS Trial (CARAT)

Acute Coronary Syndromes

United States, Australia, Netherlands, Hungary
Major Extremity Trauma Research Consortium
United States Department of Defense

Recruiting

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

Peripheral Nerve Injuries

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
NEMA Research, Inc.

Recruiting

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

Pain, Postoperative

United States
Immunophotonics, Inc.

Recruiting

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1)

Soft Tissue Sarcoma | Nonsmall Cell Lung Cancer | Metastatic Solid Tumor | Colon Cancer

France, United Kingdom, United States, Germany, Switzerland
Phoenicis Therapeutics

Recruiting

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
University of Chicago
Asphelia Pharmaceuticals

Completed

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Allergic Rhinitis

United States
Neuraptive Therapeutics Inc.

Terminated

A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Facial Paralysis

United States
Neuraptive Therapeutics Inc.

Temporarily not available

NTX-001 to Repair Peripheral Nerve Transection(s)

Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves

United States
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Toll Biotech Co. Ltd. (Beijing)

Recruiting

A Study of Single and Multiple Oral Doses of TollB-001

Rheumatoid Arthritis

China
Pinotbio, Inc.

Completed

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Mahana Therapeutics

Completed

MHNA-001 for Young Adults With IBS

Irritable Bowel Syndrome

United States
Fog Pharmaceuticals, Inc.

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer | Gastric Cancer | Colorectal Cancer | Solid Tumor | Metastatic Cancer | Adenomatous Polyposis Coli | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Carcinoma | Locally Advanced Solid Tumor | Non-small Cell Lung Cancer Stage IIIB | Gastroesophageal-junction Cancer | Non-Small... and other conditions

United States
University of Alabama at Birmingham

Recruiting

NTX-301 in MDS/AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Astrogen, Inc.

Recruiting

Phase III Clinical Trial to Evaluate the Efficacy and Safey of AST-001 in ASD Children

Autism Spectrum Disorder

Korea, Republic of
MediciNova

Completed

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

Interstitial Cystitis

United States
Vasomune Therapeutics, Inc.

Recruiting

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Pneumonia, Viral | Pneumonia | Acute Respiratory Distress Syndrome | Respiratory Infection | COVID-19 Acute Respiratory Distress Syndrome | Viral or Bacterial Infections

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Fab'entech

Recruiting

Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

COVID-19

Greece
Neuraptive Therapeutics Inc.

Active, not recruiting

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

Peripheral Nerve Injuries

United States
RenJi Hospital

Unknown

The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

China
Corat Therapeutics Gmbh

Recruiting

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Covid19

Germany
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Flame Biosciences

Completed

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

Healthy Subjects

United States
University of Colorado, Denver
Corvidia Therapeutics

Completed

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001 (COR-001-SC1)

Chronic Kidney Diseases

United States
MedRegen LLC
Vanderbilt University Medical Center

Not yet recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients (SUMMIT)

Respiratory Tract Diseases | Respiratory Failure | Acute Respiratory Distress Syndrome | Respiratory Distress Syndrome | Cytokine Storm
Equilibre Biopharmaceuticals B.V.

Completed

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

Safety Issues

United States
Bonti, Inc.

Completed

Study to Evaluate EB-001 in Reducing Musculoskeletal Pain

Musculoskeletal Pain

United States
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial (CHI SQUARE)

Acute Coronary Syndrome

Canada, United States, France, Netherlands
American Oriental Bioengineering, Inc.

Completed

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

Overactive Bladder

United States
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness

Active, not recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (SLO RP)

Usher Syndromes

Australia
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Anebulo Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Acute Cannabinoid Intoxication

Netherlands
Bloom Science

Completed

A Phase Ia Safety and Tolerability Study of BL-001

Healthy Volunteers

Switzerland
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Netherlands, United Kingdom, Czechia, Portugal, Hungary
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Perianal Fistula

Rectal Fistula
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
NFL Biosciences SAS

Completed

Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO) (PRECESTO)

Smoking Cessation | Nicotine Dependence

France
Bayer
Nerre Therapeutics Ltd.

Completed

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms (RELENT-1)

Post-menopausal Vasomotor Symptoms

United States
Pendulum Therapeutics

Completed

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States

Search clinical trials for: Intravenous Placebo for NTM-001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations